Biosimilars and Biobetters (2011)

SMi Presents their 2nd annual conference on... Biosimilars and Biobetters: Aligning business & science for success About the conference: Following the success of our inaugural event, SMi’s second Biosimilars and Biobetters conference shall build upon the progress made in last year’s meeting and  further develop the ideas and strategies that were debated and discussed. Specifically, how can the pharma and generics industries best approach the rapidly emerging and developing biosimilar market? How are policy makers shaping the contours of this new generic frontier, and what implications to they have for current biologic drug development and patent protection? With billions of dollars worth of biologic drugs going off patent in the next decade, this industry in set to expand at an intensive rate, and the importance of being fully informed of how you and your business will be affected is paramount. By the same token, the rewards of playing an important role in the development of biosimilars, or “Follow On Biologics”, are potentially substantial. At this conference you can expect to learn about a comprehensive range of pivotal issues in this area, not just relating to the development of the US regulatory pathway and the early steps of the EMA, but also the scientific developmental agenda of major players in the fledgling industry, the unique and exiting position of mAbs in this new arena, how Biobetters and Biosuperiors could challenge second generation biologics, and analysis of global biosimilars pricings structure. Presented by leading industry figures and stakeholders, this event is an unmissable opportunity to gather vital information and contacts to work towards an optimal position in the biosimilars market.  | Register Your Place |

Key Topics Addressed: The developing regulatory framework in advanced and developing markets The specific commercial, legal and scientific development of monoclonal antibodies Differentiated biosimilars: Debating their true value and potential Critical issues in demonstrating biosimilarity and maintaining diligent quality control Opportunities to drive a long term commercial strategy CMC in biosimilar development Interested in speaking at the conference?  Contact the Conference Producer. For sponsorship and exhibition opportunities, Contact our Sponsorship Department.

Who is chairing this event?

Day One Alan Sheppard Global Head Generics, Thought Leadership IMS Health

Day Two Richard DiCicco Chairman Harvest Moon Pharmaceuticals

Who is speaking at this event?

Peter De Veene, Deputy European Qualified Person for Pharmacovigilance Roche Anne Dollard Deputy, General Counsel and Chief Patent Counsel, Takeda Ross Lobell, Vice President Regulatory Affairs, MedImmune Anita Varma, Partner, Ropes and Gray Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals Camilla Balleny, Partner, Pinsent Masons LLP Christopher Stothers, Counsel, Intellectual Property & Antitrust Litigation, Arnold & Porter (UK) LLP Harvinder Popli Director and Head In- Licensing Ranbaxy Labs Jean-Yves le Cotonnec Managing Partner, Founder & CEO TRISKEL Integrated Services S.A. Elisabeth Berthet Lawyer at the Paris Bar Armengaud-Guerlain Louis-Christian Clauss Senior Consultant  Health Care Atheln Biomed Frank Scappaticci Associate Group Medical Director Genentech Alan Sheppard Global Head Generics, Thought Leadership IMS Health Richard Littlewood Founding Partner Applied Strategic LLP Carsten Brockmeyer MD Brockmeyer Biopharma Hans-Martin Mueller Associate Director, Biotech Development Merck